Lansoprazole, imported in 15 mg and 30 mg delayed-release (DR) tablets, is a proton-pump inhibitor (PPI). It is used to reduce gastric acid secretion and for the short term treatment of active gastric ulcers, active duodenal ulcers, erosive reflux oesophagitis, symptomatic gastroesophageal reflux disease, and non-steroidal anti-inflammatory drug (NSAID) induced gastric and duodenal ulcers.
[1] Please importantly note that only the relevant portion of the related is displayed above. You may refer to the said customs ruling for the entire ruling explanation.
[1]. https://rulings.cbp.gov/ruling/N323546